Krystal Biotech, Inc. $KRYS Shares Purchased by GW&K Investment Management LLC

GW&K Investment Management LLC lifted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 575.7% in the 3rd quarter, Holdings Channel reports. The firm owned 123,611 shares of the company’s stock after buying an additional 105,316 shares during the quarter. GW&K Investment Management LLC’s holdings in Krystal Biotech were worth $41,110,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of KRYS. Private Advisor Group LLC acquired a new position in Krystal Biotech during the third quarter worth $444,000. Global Retirement Partners LLC raised its holdings in Krystal Biotech by 38.3% during the third quarter. Global Retirement Partners LLC now owns 718 shares of the company’s stock valued at $239,000 after buying an additional 199 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its holdings in Krystal Biotech by 27.1% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 8,208 shares of the company’s stock valued at $2,730,000 after buying an additional 1,750 shares in the last quarter. HighTower Advisors LLC lifted its position in shares of Krystal Biotech by 12.4% in the third quarter. HighTower Advisors LLC now owns 2,394 shares of the company’s stock worth $796,000 after buying an additional 265 shares during the last quarter. Finally, Hantz Financial Services Inc. lifted its position in shares of Krystal Biotech by 49.0% in the third quarter. Hantz Financial Services Inc. now owns 693 shares of the company’s stock worth $230,000 after buying an additional 228 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Citigroup lowered their price objective on Krystal Biotech from $416.00 to $412.00 and set a “buy” rating on the stock in a report on Tuesday, November 3rd. Weiss Ratings lowered Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, November 4th. HC Wainwright restated a “buy” rating and issued a $361.00 target price on shares of Krystal Biotech in a report on Thursday, October 15th. William Blair raised Krystal Biotech to a “strong-buy” rating in a research report on Wednesday, September 23rd. Finally, Zacks Research downgraded Krystal Biotech from a “hold” rating to a “strong sell” rating in a report on Friday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Krystal Biotech has a consensus rating of “Moderate Buy” and a consensus target price of $375.00.

Get Our Latest Report on Krystal Biotech

Krystal Biotech Price Performance

Krystal Biotech stock opened at $308.57 on Friday. Krystal Biotech, Inc. has a fifty-two week low of $203.35 and a fifty-two week high of $382.54. The firm has a fifty day moving average price of $322.48 and a two-hundred day moving average price of $310.42. The firm has a market cap of $9.14 billion, a price-to-earnings ratio of 40.42 and a beta of 0.56.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.26. The company had revenue of $127.34 million for the quarter, compared to the consensus estimate of $125.77 million. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. As a group, sell-side analysts expect that Krystal Biotech, Inc. will post 7.74 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the sale, the insider owned 1,302,145 shares in the company, valued at $467,886,741.40. This represents a 1.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.10% of the company’s stock.

Krystal Biotech Profile

(Free Report)

Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.

Read More

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report).

Institutional Ownership by Quarter for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.